Home › NDC Lookup › RxCUI directory › RxCUI 2049858

Elagolix 150 MG Oral Tablet [Orilissa] — RxCUI 2049858

RxNorm drug concept · Semantic branded drug
RxCUI 2049858 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2049858
Official nameElagolix 150 MG Oral Tablet [Orilissa]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asOrilissa 150 MG Oral Tablet
FDA products mapped2
Package NDCs mapped4
Reported Medicaid activity (SDUD)15,622 prescriptions · 44 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Elagolix: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Orilissa is designed to reduce the pain that comes with endometriosis — including daily pelvic pain and pain during sex. It does this by lowering your estrogen levels, which quiets...
  • What exactly is Orilissa supposed to do for my endometriosis?
  • That's a great question and something really worth understanding. Elagolix lowers estrogen, and lower estrogen over time leads to bone loss — similar to what happens after menopaus...
  • Why can I only take it for a limited time?
📖 Read our full Elagolix guide →

🕸️ Concept Web — How Elagolix 150 MG Oral Tablet [Orilissa] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Elagolix 150 MG Oral Tablet [Orilissa] RxCUI 2049858

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Elagolix 2049846
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Orilissa 2049853
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Elagolix Oral Tablet 2049851
    • Elagolix Oral Product 2049849
    • Elagolix Pill 2049850
    • Elagolix Oral Tablet [Orilissa] 2049855
    • Orilissa Oral Product 2049856
    • Orilissa Pill 2049857
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Elagolix 150 MG Oral Tablet SCD · 2049852
  • Elagolix 150 MG SCDC · 2049848
  • Elagolix Oral Tablet SCDF · 2049851
  • Elagolix Oral Product SCDG · 2049849
  • Elagolix Pill SCDG · 2049850

Brand-Name Concepts

  • Elagolix 150 MG [Orilissa] SBDC · 2049854
  • Elagolix Oral Tablet [Orilissa] SBDF · 2049855
  • Orilissa Oral Product SBDG · 2049856
  • Orilissa Pill SBDG · 2049857
  • Orilissa BN · 2049853

📦 FDA Products & Package NDCs

2 products · 4 package NDCs
4 package NDCs map to RxCUI 2049858 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00074-0038-07 1 BLISTER PACK in 1 CARTON (0074-0038-07) / 7 TABLET, FILM... Orilissa AbbVie Inc. 2018-07-23
00074-0038-28 4 BLISTER PACK in 1 CARTON (0074-0038-28) / 7 TABLET, FILM... Orilissa AbbVie Inc. 2018-07-23
00074-0039-14 1 BLISTER PACK in 1 CARTON (0074-0039-14) / 14 TABLET, FILM... Orilissa AbbVie Inc. 2018-07-23
00074-0039-56 4 BLISTER PACK in 1 CARTON (0074-0039-56) / 14 TABLET, FILM... Orilissa AbbVie Inc. 2018-07-23
Observed labelers: AbbVie Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.